A PYMNTS Company

Mexico: COFECE asked to investigate corruption in pharmaceuticals

By  |  March 19, 2019
Alfonso Ramírez Cuellar, President of the Budget and Public Accounts Committee of the Chamber of Deputies of Mexico, has asked the Federal Commission for Economic Competition (COFECE) to begin investigations to detect pharmaceutical companies involved in corruption cases, in order to prevent their participation in future tenders.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Some pharmaceutical companies, including marketers and distributors of drugs, have been involved in crimes such as bribery, data omission, price manipulation and monopolistic practices, affecting consumers across the country.

    At the beginning of 2018, COFECE declared that it had evidence of unauthorized mergers in this market, including medicines, hygiene products and personal care products.
    Full Content: El Sol de México

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.